Erasca revamps pipeline, laying off staff as it licenses cancer drugs from China and nabs $160M
Erasca is looking for a refresh as it drops several early-stage cancer assets, picks up new ones from China and raises cash to help push …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
